Prostate Cancer - Pipeline Review, H2 2011

Document Sample
Prostate Cancer - Pipeline Review, H2 2011 Powered By Docstoc
					Prostate Cancer – Pipeline Review, H2 2011




                   Prostate Cancer - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1304IDB

                                                                                          Publication Date: September 2011




Prostate Cancer – Pipeline Review, H2 2011                                                                    GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                 Page(1)
Prostate Cancer – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                       16
List of Figures                                                                                                      25
Introduction                                                                                                         26
     Global Markets Direct Report Coverage                                                                           26
Prostate Cancer Overview                                                                                             27
Therapeutics Development                                                                                             28
     An Overview of Pipeline Products for Prostate Cancer                                                            28
Prostate Cancer Therapeutics under Development by Companies                                                          30
Prostate Cancer Therapeutics under Investigation by Universities/Institutes                                          40
Late Stage Products                                                                                                  53
     Comparative Analysis                                                                                            53
Mid Clinical Stage Products                                                                                          54
     Comparative Analysis                                                                                            54
Early Clinical Stage Products                                                                                        55
     Comparative Analysis                                                                                            55
Discovery and Pre-Clinical Stage Products                                                                            56
     Comparative Analysis                                                                                            56
Prostate Cancer Therapeutics - Products under Development by Companies                                               57
Prostate Cancer Therapeutics - Products under Investigation by Universities/Institutes                               80
Companies Involved in Prostate Cancer Therapeutics Development                                                      113
     Bristol-Myers Squibb Company                                                                                   113
     Genzyme Corporation                                                                                            113
     Johnson & Johnson                                                                                              114
     Boehringer Ingelheim GmbH                                                                                      114
     F. Hoffmann-La Roche Ltd.                                                                                      115
     Kyowa Hakko Kirin Co., Ltd.                                                                                    115
     Abbott Laboratories                                                                                            116
     Amgen Inc.                                                                                                     116
     Sanofi-Aventis                                                                                                 117
     Adherex Technologies Inc.                                                                                      117
     AstraZeneca PLC                                                                                                118
     Eli Lilly and Company                                                                                          118
     Viralytics Ltd.                                                                                                119
     Bioniche Life Sciences, Inc.                                                                                   119
     Genentech, Inc.                                                                                                120
     Nektar Therapeutics                                                                                            120
     Inovio Biomedical Corporation                                                                                  121
     Bavarian Nordic A/S                                                                                            121
     Isis Pharmaceuticals, Inc.                                                                                     122
     GenVec, Inc.                                                                                                   122
     Merck & Co., Inc.                                                                                              123
     AbGenomics International, Inc.                                                                                 123
     United Biomedical, Inc.                                                                                        124
     Oxford BioMedica plc                                                                                           124
     Micromet, Inc.                                                                                                 125
     Infinity Pharmaceuticals, Inc.                                                                                 125


Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(2)
Prostate Cancer – Pipeline Review, H2 2011


     Generex Biotechnology Corporation                                                                              126
     Takeda Pharmaceutical Company Limited                                                                          126
     Albany Molecular Research, Inc.                                                                                127
     YM BioSciences Inc.                                                                                            127
     Light Sciences Oncology, Inc.                                                                                  128
     Ipsen S.A.                                                                                                     128
     Panacea Pharmaceuticals, Inc.                                                                                  129
     Bio-Path Holdings, Inc.                                                                                        129
     Ambrilia Biopharma Inc.                                                                                        130
     BioSante Pharmaceuticals, Inc.                                                                                 130
     Novartis AG                                                                                                    130
     Aphios Corporation                                                                                             131
     ImClone Systems Incorporated                                                                                   132
     Astellas Pharma Inc.                                                                                           132
     BioMarin Pharmaceutical Inc.                                                                                   133
     Cephalon, Inc.                                                                                                 133
     Eisai Co., Ltd.                                                                                                134
     Genta Incorporated                                                                                             134
     GTx, Inc.                                                                                                      135
     Hanmi Pharmaceutical Co Ltd                                                                                    135
     Nippon Shinyaku Co., Ltd.                                                                                      136
     Orion Corporation                                                                                              136
     Pfizer Inc.                                                                                                    137
     SuperGen, Inc.                                                                                                 137
     Taiho Pharmaceutical Co., Ltd.                                                                                 138
     Cell Therapeutics, Inc.                                                                                        138
     Progenics Pharmaceuticals, Inc.                                                                                139
     Enzon Pharmaceuticals, Inc.                                                                                    139
     ENKAM Pharmaceuticals A/S                                                                                      140
     Exelixis, Inc.                                                                                                 140
     Aduro BioTech                                                                                                  141
     Menarini Group                                                                                                 141
     Celgene Corporation                                                                                            141
     Bayer AG                                                                                                       142
     Attenuon, LLC                                                                                                  142
     Incyte Corporation                                                                                             143
     Geron Corporation                                                                                              143
     Merck KGaA                                                                                                     144
     Access Pharmaceuticals, Inc.                                                                                   144
     Advaxis, Inc.                                                                                                  145
     Alchemia Limited                                                                                               145
     Addex Pharmaceuticals                                                                                          146
     Genesis Research and Development Corporation Ltd.                                                              146
     GW Pharmaceuticals plc                                                                                         147
     Hollis-Eden Pharmaceuticals, Inc.                                                                              147
     Celldex Therapeutics, Inc.                                                                                     148
     Anavex Life Sciences Corp.                                                                                     148
     ValiRx Plc                                                                                                     149




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(3)
Prostate Cancer – Pipeline Review, H2 2011


     Active Biotech AB                                                                                              149
     AEterna Zentaris Inc.                                                                                          150
     Antisense Therapeutics Limited                                                                                 150
     Marshall Edwards, Inc.                                                                                         151
     Bionomics Limited                                                                                              151
     Molecular Insight Pharmaceuticals, Inc.                                                                        152
     Neuren Pharmaceuticals Limited                                                                                 152
     Northwest Biotherapeutics, Inc.                                                                                153
     Circadian Technologies Limited                                                                                 153
     Cleveland BioLabs, Inc.                                                                                        154
     Oncolytics Biotech Inc.                                                                                        154
     Oncothyreon Inc                                                                                                155
     OncoVista Innovative Therapies, Inc.                                                                           155
     Compugen Ltd.                                                                                                  156
     Osta Biotechnologies Inc.                                                                                      156
     Patrys Limited                                                                                                 157
     Peregrine Pharmaceuticals, Inc.                                                                                157
     Medivation, Inc.                                                                                               158
     Keryx Biopharmaceuticals, Inc.                                                                                 158
     ADVENTRX Pharmaceuticals                                                                                       159
     Telik, Inc.                                                                                                    159
     Transcept Pharmaceuticals, Inc.                                                                                160
     Soligenix, Inc.                                                                                                160
     Poniard Pharmaceuticals, Inc.                                                                                  161
     Regeneron Pharmaceuticals, Inc.                                                                                161
     Champions Biotechnology, Inc.                                                                                  162
     Repros Therapeutics Inc.                                                                                       162
     Oncogenex Pharmaceuticals, Inc.                                                                                163
     ProMetic Life Sciences Inc.                                                                                    164
     Progen Pharmaceuticals Limited                                                                                 164
     TapImmune Inc.                                                                                                 165
     Quest PharmaTech Inc.                                                                                          165
     Threshold Pharmaceuticals, Inc.                                                                                166
     Synta Pharmaceuticals Corp.                                                                                    166
     Sareum Holdings plc                                                                                            167
     Oasmia Pharmaceutical AB                                                                                       167
     Protox Therapeutics Inc.                                                                                       168
     e-Therapeutics plc                                                                                             168
     RXi Pharmaceuticals Corporation                                                                                169
     Hybrigenics S.A.                                                                                               169
     Rexahn Pharmaceuticals, Inc.                                                                                   170
     Merrion Pharmaceuticals Plc                                                                                    170
     Emiliem, Inc.                                                                                                  171
     Oryzon                                                                                                         171
     Angelini Group                                                                                                 172
     Affitech A/S                                                                                                   172
     Debiopharm Group                                                                                               173
     Antisense Pharma GmbH                                                                                          173




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(4)
Prostate Cancer – Pipeline Review, H2 2011


     Chipscreen Biosciences Ltd                                                                                     173
     INSYS Therapeutics, Inc.                                                                                       174
     Biotecnol SA                                                                                                   174
     Camurus AB                                                                                                     175
     Immupharma Plc                                                                                                 175
     Actis Biologics, Inc                                                                                           176
     Med Discovery SA                                                                                               176
     Cadila Pharmaceuticals Ltd.                                                                                    177
     ERYtech Pharma                                                                                                 177
     Pro-Cure Therapeutics Limited                                                                                  177
     Vaxon Biotech                                                                                                  178
     Advantagene, Inc.                                                                                              178
     CureVac GmbH                                                                                                   179
     Alethia Biotherapeutics Inc.                                                                                   179
     GenSpera, Inc.                                                                                                 179
     Cellectis S.A.                                                                                                 180
     Ascenta Therapeutics, Inc.                                                                                     180
     Tokai Pharmaceuticals, Inc.                                                                                    181
     MacroGenics, Inc.                                                                                              181
     Pervasis Therapeutics, Inc.                                                                                    182
     Antyra, Inc.                                                                                                   182
     Unibioscreen S.A.                                                                                              182
     Cytochroma Inc.                                                                                                183
     Pantarhei Bioscience BV                                                                                        183
     Azaya Therapeutics, Inc.                                                                                       183
     GP Pharm, S.A.                                                                                                 184
     S*BIO Pte Ltd                                                                                                  184
     IC-MedTech, Inc.                                                                                               185
     Iconic Therapeutics, Inc.                                                                                      185
     ProNAi Therapeutics, Inc.                                                                                      185
     Jennerex Biotherapeutics, Inc.                                                                                 186
     Oakwood Laboratories L.L.C.                                                                                    186
     Axelar AB                                                                                                      187
     Endocyte, Inc.                                                                                                 187
     Polyphenon Pharma                                                                                              188
     Omnitura Therapeutics Inc.                                                                                     188
     Pharminox Limited                                                                                              188
     Esperance Pharmaceuticals, Inc.                                                                                189
     Mirna Therapeutics, Inc.                                                                                       189
     Transtech Pharma, Inc.                                                                                         190
     ImmunoVaccine Technologies Inc.                                                                                190
     Welichem Biotech Inc.                                                                                          191
     Peptron, Inc.                                                                                                  191
     GENova Biotherapeutics, Inc.                                                                                   191
     Etubics Corporation                                                                                            192
     TSD Japan, Inc.                                                                                                192
     BIND Biosciences, Inc.                                                                                         193
     Molecular Design International, Inc.                                                                           193




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(5)
Prostate Cancer – Pipeline Review, H2 2011


     NewLink Genetics Corporation                                                                                   193
     PepTcell Limited                                                                                               194
     PharmaMar, S.A.                                                                                                194
     Genetic Immunity, LLC                                                                                          195
     Quintessence Biosciences, Inc.                                                                                 195
     Bellicum Pharmaceuticals, Inc.                                                                                 195
     Virax Holdings Limited                                                                                         196
     AmpliMed Corporation                                                                                           196
     Aprea AB.                                                                                                      197
     Kinex Pharmaceuticals, LLC                                                                                     197
     Adamis Pharmaceuticals Corporation                                                                             197
     Tigris Pharmaceuticals, Inc.                                                                                   198
     Cylene Pharmaceuticals, Inc.                                                                                   198
     IRX Therapeutics, Inc.                                                                                         199
     TRACON Pharmaceuticals, Inc.                                                                                   199
     Archer Biosciences, Inc                                                                                        199
     Nometics Inc.                                                                                                  200
     Ferring Pharmaceuticals, Inc.                                                                                  200
     Advanced Cancer Therapeutics                                                                                   201
     EUSA Pharma, Inc.                                                                                              201
     Kotinos Pharmaceuticals, Inc.                                                                                  202
     Cellceutix Pharmaceuticals, Inc.                                                                               202
     Acuvax Ltd                                                                                                     202
     British Canadian Biosciences Corp.                                                                             203
     Aragon Pharmaceuticals, Inc.                                                                                   203
     Vakzine Projekt Management GmbH                                                                                203
     Pepscan Therapeutics                                                                                           204
     Vaxonco                                                                                                        204
     Medical Marketing International Group plc                                                                      204
     Ausio Pharmaceuticals, LLC                                                                                     205
     Errant Gene Therapeutics, LLC                                                                                  206
     Polaris Group                                                                                                  206
     ImQuest Life Sciences                                                                                          206
     CytoVac A/S                                                                                                    207
Prostate Cancer - Therapeutics Assessment                                                                           208
     Assessment by Monotherapy Products                                                                             208
     Assessment by Combination Products                                                                             209
     Assessment by Route of Administration                                                                          210
     Assessment by Molecule Type                                                                                    213
Late Stage Drug Profiles                                                                                            216
     Yervoy - Drug Profile                                                                                          216
          Product Description                                                                                       216
          Mechanism of Action                                                                                       216
          R&D Progress                                                                                              216
     Firmagon - Drug Profile                                                                                        217
          Product Description                                                                                       217
          Mechanism of Action                                                                                       217
          R&D Progress                                                                                              217




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(6)
Prostate Cancer – Pipeline Review, H2 2011


     TAK-700 - Drug Profile                                                                                         218
          Product Description                                                                                       218
          Mechanism of Action                                                                                       218
          R&D Progress                                                                                              218
     Sutent - Drug Profile                                                                                          219
          Product Description                                                                                       219
          Mechanism of Action                                                                                       219
          R&D Progress                                                                                              219
     Acapodene - Drug Profile                                                                                       221
          Product Description                                                                                       221
          Mechanism of Action                                                                                       221
          R&D Progress                                                                                              221
     OGX-011 - Drug Profile                                                                                         223
          Product Description                                                                                       223
          Mechanism of Action                                                                                       223
          R&D Progress                                                                                              223
     TASQ - Drug Profile                                                                                            225
          Product Description                                                                                       225
          Mechanism of Action                                                                                       225
          R&D Progress                                                                                              225
     MDV3100 - Drug Profile                                                                                         226
          Product Description                                                                                       226
          Mechanism of Action                                                                                       226
          R&D Progress                                                                                              226
     Pamorelin - Drug Profile                                                                                       228
          Product Description                                                                                       228
          Mechanism of Action                                                                                       228
          R&D Progress                                                                                              228
     XRP6258 - Drug Profile                                                                                         229
          Product Description                                                                                       229
          Mechanism of Action                                                                                       229
          R&D Progress                                                                                              229
     Leuprolide - Drug Profile                                                                                      230
          Product Description                                                                                       230
          Mechanism of Action                                                                                       230
          R&D Progress                                                                                              230
     Leuprolide 7.5 mg - Drug Profile                                                                               231
          Product Description                                                                                       231
          Mechanism of Action                                                                                       231
          R&D Progress                                                                                              231
     DCVax-Prostate - Drug Profile                                                                                  232
          Product Description                                                                                       232
          Mechanism of Action                                                                                       232
          R&D Progress                                                                                              232
     NV06 - Drug Profile                                                                                            233
          Product Description                                                                                       233
          Mechanism of Action                                                                                       233
          R&D Progress                                                                                              233




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(7)
Prostate Cancer – Pipeline Review, H2 2011


     Dutasteride - Drug Profile                                                                                     234
          Product Description                                                                                       234
          Mechanism of Action                                                                                       234
          R&D Progress                                                                                              234
     Antiandrogen Therapy + LHRH agonist - Drug Profile                                                             235
          Product Description                                                                                       235
          Mechanism of Action                                                                                       235
          R&D Progress                                                                                              235
     Androgen Blockade Therapy + Zoledronic Acid - Drug Profile                                                     237
          Product Description                                                                                       237
          Mechanism of Action                                                                                       237
          R&D Progress                                                                                              237
     Radiation Therapy + Bicalutamide + Goserelin - Drug Profile                                                    238
          Product Description                                                                                       238
          Mechanism of Action                                                                                       238
          R&D Progress                                                                                              238
     Radiation Therapy + Bicalutamide - Drug Profile                                                                239
          Product Description                                                                                       239
          Mechanism of Action                                                                                       239
          R&D Progress                                                                                              239
     Radiation Therapy + Androgen Deprivation Therapy - Drug Profile                                                241
          Product Description                                                                                       241
          Mechanism of Action                                                                                       241
          R&D Progress                                                                                              241
     Radiation Therapy + Leuprolide Acetate - Drug Profile                                                          243
          Product Description                                                                                       243
          Mechanism of Action                                                                                       243
          R&D Progress                                                                                              243
     Hormone Therapy + Docetaxel + Estramustine - Drug Profile                                                      245
          Product Description                                                                                       245
          Mechanism of Action                                                                                       245
          R&D Progress                                                                                              246
     Hormone Therapy - Drug Profile                                                                                 247
          Product Description                                                                                       247
          Mechanism of Action                                                                                       247
          R&D Progress                                                                                              248
     Docetaxel + Gefitinib - Drug Profile                                                                           249
          Product Description                                                                                       249
          Mechanism of Action                                                                                       249
          R&D Progress                                                                                              249
     Goserelin + Bicalutamide - Drug Profile                                                                        250
          Product Description                                                                                       250
          Mechanism of Action                                                                                       250
          R&D Progress                                                                                              250
     Androgen suppression + Zoledronate - Drug Profile                                                              251
          Product Description                                                                                       251
          Mechanism of Action                                                                                       251
          R&D Progress                                                                                              251




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                              Page(8)
Prostate Cancer – Pipeline Review, H2 2011


     Dalteparin - Drug Profile                                                                                              252
          Product Description                                                                                               252
          Mechanism of Action                                                                                               252
          R&D Progress                                                                                                      252
     Androgen suppression + Docetaxel + Prednisolone - Drug Profile                                                         253
          Product Description                                                                                               253
          Mechanism of Action                                                                                               253
          R&D Progress                                                                                                      253
     Androgen suppression + Celecoxib - Drug Profile                                                                        254
          Product Description                                                                                               254
          Mechanism of Action                                                                                               254
          R&D Progress                                                                                                      254
     Androgen suppression + Zoledronate + Celecoxib - Drug Profile                                                          255
          Product Description                                                                                               255
          Mechanism of Action                                                                                               255
          R&D Progress                                                                                                      255
     Androgen suppression + Zoledronate + Docetaxel + Prednisolone - Drug Profile                                           256
          Product Description                                                                                               256
          Mechanism of Action                                                                                               256
          R&D Progress                                                                                                      256
     Goserelin + Bicalutamide + Mitoxantrone + Prednisone - Drug Profile                                                    258
          Product Description                                                                                               258
          Mechanism of Action                                                                                               258
          R&D Progress                                                                                                      258
     Doxorubicin Hydrochloride + Estramustine Phosphate Sodium + Ketoconazole + Vinblastine - Drug Profile                  260
          Product Description                                                                                               260
          Mechanism of Action                                                                                               260
          R&D Progress                                                                                                      260
     Docetaxel + Prednisone - Drug Profile                                                                                  262
          Product Description                                                                                               262
          Mechanism of Action                                                                                               262
          R&D Progress                                                                                                      262
     Doxorubicin Hydrochloride + Strontium chloride Sr 89 - Drug Profile                                                    263
          Product Description                                                                                               263
          Mechanism of Action                                                                                               263
          R&D Progress                                                                                                      263
     Docetaxel + Prednisone + Doxorubicin Hydrochloride - Drug Profile                                                      265
          Product Description                                                                                               265
          Mechanism of Action                                                                                               265
          R&D Progress                                                                                                      265
     Radiation Therapy + Casodex - Drug Profile                                                                             267
          Product Description                                                                                               267
          Mechanism of Action                                                                                               267
          R&D Progress                                                                                                      267
     Dutasteride - Drug Profile                                                                                             268
          Product Description                                                                                               268
          Mechanism of Action                                                                                               268
          R&D Progress                                                                                                      268




Prostate Cancer – Pipeline Review, H2 2011                                                        GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                      Page(9)
Prostate Cancer – Pipeline Review, H2 2011


     Xinlay - Drug Profile                                                                                          269
          Product Description                                                                                       269
          Mechanism of Action                                                                                       269
          R&D Progress                                                                                              269
     Lutrate Depot - Drug Profile                                                                                   271
          Product Description                                                                                       271
          Mechanism of Action                                                                                       271
          R&D Progress                                                                                              271
     Lutrate Depot - Drug Profile                                                                                   272
          Product Description                                                                                       272
          Mechanism of Action                                                                                       272
          R&D Progress                                                                                              272
     Zibotentan + Taxotere - Drug Profile                                                                           273
          Product Description                                                                                       273
          Mechanism of Action                                                                                       273
          R&D Progress                                                                                              273
     Asentar + Taxotere - Drug Profile                                                                              274
          Product Description                                                                                       274
          Mechanism of Action                                                                                       274
          R&D Progress                                                                                              274
     Eligard + Taxotere - Drug Profile                                                                              276
          Product Description                                                                                       276
          Mechanism of Action                                                                                       276
          R&D Progress                                                                                              276
     Revlimid - Drug Profile                                                                                        277
          Product Description                                                                                       277
          Mechanism of Action                                                                                       277
          R&D Progress                                                                                              277
     Sprycel + Docetaxel + Prednisone - Drug Profile                                                                279
          Product Description                                                                                       279
          Mechanism of Action                                                                                       279
          R&D Progress                                                                                              279
     Leuproreline + Flutamide - Drug Profile                                                                        280
          Product Description                                                                                       280
          Mechanism of Action                                                                                       280
          R&D Progress                                                                                              280
     Gestoral - Drug Profile                                                                                        281
          Product Description                                                                                       281
          Mechanism of Action                                                                                       281
          R&D Progress                                                                                              281
     Zoledronic Acid - Drug Profile                                                                                 282
          Product Description                                                                                       282
          Mechanism of Action                                                                                       282
          R&D Progress                                                                                              282
     Custirsen Sodium + Prednisone + Docetaxel - Drug Profile                                                       283
          Product Description                                                                                       283
          Mechanism of Action                                                                                       283
          R&D Progress                                                                                              283




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(10)
Prostate Cancer – Pipeline Review, H2 2011


     Rapamune - Drug Profile                                                                                        285
          Product Description                                                                                       285
          Mechanism of Action                                                                                       285
          R&D Progress                                                                                              285
     Ciprofloxacine - Drug Profile                                                                                  286
          Product Description                                                                                       286
          Mechanism of Action                                                                                       286
          R&D Progress                                                                                              286
     Bevacizumab + Docetaxel + Prednisone - Drug Profile                                                            287
          Product Description                                                                                       287
          Mechanism of Action                                                                                       287
          R&D Progress                                                                                              287
     Docetaxel + Androgen Deprivation Therapy - Drug Profile                                                        289
          Product Description                                                                                       289
          Mechanism of Action                                                                                       289
          R&D Progress                                                                                              289
     Methylprednisolone + Doxorubicin - Drug Profile                                                                291
          Product Description                                                                                       291
          Mechanism of Action                                                                                       291
          R&D Progress                                                                                              291
     Methylprednisolone - Drug Profile                                                                              292
          Product Description                                                                                       292
          Mechanism of Action                                                                                       292
          R&D Progress                                                                                              292
     AG3340 + Mitoxantrone + Prednisone - Drug Profile                                                              293
          Product Description                                                                                       293
          Mechanism of Action                                                                                       293
          R&D Progress                                                                                              293
     Ipilimumab + Radiation Therapy - Drug Profile                                                                  294
          Product Description                                                                                       294
          Mechanism of Action                                                                                       294
          R&D Progress                                                                                              294
     Suramin - Drug Profile                                                                                         295
          Product Description                                                                                       295
          Mechanism of Action                                                                                       295
          R&D Progress                                                                                              295
     Bicalutamide + Goserelin + Radiation Therapy - Drug Profile                                                    296
          Product Description                                                                                       296
          Mechanism of Action                                                                                       296
          R&D Progress                                                                                              296
     Docetaxel - Drug Profile                                                                                       298
          Product Description                                                                                       298
          Mechanism of Action                                                                                       298
          R&D Progress                                                                                              298
     Docetaxel + Prednisone + Vatalanib - Drug Profile                                                              299
          Product Description                                                                                       299
          Mechanism of Action                                                                                       299
          R&D Progress                                                                                              300




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(11)
Prostate Cancer – Pipeline Review, H2 2011


     Thalidomide + Leuprolide Acetate + Goserelin - Drug Profile                                                    301
          Product Description                                                                                       301
          Mechanism of Action                                                                                       301
          R&D Progress                                                                                              301
     Bicalutamide + Goserelin - Drug Profile                                                                        303
          Product Description                                                                                       303
          Mechanism of Action                                                                                       303
          R&D Progress                                                                                              303
     Docetaxel + Prednisone - Drug Profile                                                                          305
          Product Description                                                                                       305
          Mechanism of Action                                                                                       305
          R&D Progress                                                                                              305
     Docetaxel + Risedronate + Prednisone - Drug Profile                                                            306
          Product Description                                                                                       306
          Mechanism of Action                                                                                       306
          R&D Progress                                                                                              306
     Aflibercept + Taxotere + Prednisone - Drug Profile                                                             307
          Product Description                                                                                       307
          Mechanism of Action                                                                                       307
          R&D Progress                                                                                              307
     Bicalutamide - Drug Profile                                                                                    309
          Product Description                                                                                       309
          Mechanism of Action                                                                                       309
          R&D Progress                                                                                              309
     Bicalutamide + Goserelin Acetate - Drug Profile                                                                310
          Product Description                                                                                       310
          Mechanism of Action                                                                                       310
          R&D Progress                                                                                              310
     GM2-KLH + QS21 - Drug Profile                                                                                  311
          Product Description                                                                                       311
          Mechanism of Action                                                                                       311
          R&D Progress                                                                                              311
     Docetaxel + Hormonal Therapy - Drug Profile                                                                    313
          Product Description                                                                                       313
          Mechanism of Action                                                                                       313
          R&D Progress                                                                                              313
     Dexamethasone - Drug Profile                                                                                   314
          Product Description                                                                                       314
          Mechanism of Action                                                                                       314
          R&D Progress                                                                                              314
     Ad5-yCD/mutTKSR39rep-ADP + Radiation Therapy - Drug Profile                                                    315
          Product Description                                                                                       315
          Mechanism of Action                                                                                       315
          R&D Progress                                                                                              315
     Eulexin + Zoladex - Drug Profile                                                                               316
          Product Description                                                                                       316
          Mechanism of Action                                                                                       316
          R&D Progress                                                                                              316




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(12)
Prostate Cancer – Pipeline Review, H2 2011


     Eulexin + Lupron - Drug Profile                                                                                317
          Product Description                                                                                       317
          Mechanism of Action                                                                                       317
          R&D Progress                                                                                              317
     antiandrogen therapy + docetaxel + goserelin - Drug Profile                                                    318
          Product Description                                                                                       318
          Mechanism of Action                                                                                       318
          R&D Progress                                                                                              318
     celecoxib + docetaxel + prednisolone + zoledronic acid - Drug Profile                                          319
          Product Description                                                                                       319
          Mechanism of Action                                                                                       319
          R&D Progress                                                                                              320
     antiandrogen therapy + docetaxel - Drug Profile                                                                321
          Product Description                                                                                       321
          Mechanism of Action                                                                                       321
          R&D Progress                                                                                              321
     Triptorelin + Radiation theraphy - Drug Profile                                                                323
          Product Description                                                                                       323
          Mechanism of Action                                                                                       323
          R&D Progress                                                                                              323
     Mitoxantrone + Prednisone + Clodronate - Drug Profile                                                          324
          Product Description                                                                                       324
          Mechanism of Action                                                                                       324
          R&D Progress                                                                                              324
     Flutamide + Goserelin + Radiation therpahy - Drug Profile                                                      326
          Product Description                                                                                       326
          Mechanism of Action                                                                                       326
          R&D Progress                                                                                              327
     Flutamide + Goserelin + Leuprolide Acetate + Radiation Therapy - Drug Profile                                  328
          Product Description                                                                                       328
          Mechanism of Action                                                                                       328
          R&D Progress                                                                                              329
     estramustine + docetaxel - Drug Profile                                                                        330
          Product Description                                                                                       330
          Mechanism of Action                                                                                       330
          R&D Progress                                                                                              330
     Meloxicam - Drug Profile                                                                                       331
          Product Description                                                                                       331
          Mechanism of Action                                                                                       331
          R&D Progress                                                                                              331
     Goserelin - Drug Profile                                                                                       332
          Product Description                                                                                       332
          Mechanism of Action                                                                                       332
          R&D Progress                                                                                              332
     Dexamethasone - Drug Profile                                                                                   333
          Product Description                                                                                       333
          Mechanism of Action                                                                                       333
          R&D Progress                                                                                              333




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(13)
Prostate Cancer – Pipeline Review, H2 2011


     Docetaxel + Prednisone - Drug Profile                                                                          334
          Product Description                                                                                       334
          Mechanism of Action                                                                                       334
          R&D Progress                                                                                              334
     Dutasteride - Drug Profile                                                                                     335
          Product Description                                                                                       335
          Mechanism of Action                                                                                       335
          R&D Progress                                                                                              335
     Flutamide + Goserelin Acetate + Low-LET Photon Therapy - Drug Profile                                          336
          Product Description                                                                                       336
          Mechanism of Action                                                                                       336
          R&D Progress                                                                                              336
     Gemcitabine + Cisplatin - Drug Profile                                                                         338
          Product Description                                                                                       338
          Mechanism of Action                                                                                       338
          R&D Progress                                                                                              338
     Ketoconazole + Hydrocortisone - Drug Profile                                                                   340
          Product Description                                                                                       340
          Mechanism of Action                                                                                       340
          R&D Progress                                                                                              340
     Mitoxantrone + Prednisone - Drug Profile                                                                       342
          Product Description                                                                                       342
          Mechanism of Action                                                                                       342
          R&D Progress                                                                                              342
     TAK-700 + Prednisone - Drug Profile                                                                            343
          Product Description                                                                                       343
          Mechanism of Action                                                                                       343
          R&D Progress                                                                                              343
     Docetaxel - Drug Profile                                                                                       344
          Product Description                                                                                       344
          Mechanism of Action                                                                                       344
          R&D Progress                                                                                              344
     Zaltrap - Drug Profile                                                                                         345
          Product Description                                                                                       345
          Mechanism of Action                                                                                       345
          R&D Progress                                                                                              345
     Docetaxel - Drug Profile                                                                                       347
          Product Description                                                                                       347
          Mechanism of Action                                                                                       347
          R&D Progress                                                                                              347
     Aflibercept + Docetaxel + Prednisone - Drug Profile                                                            348
          Product Description                                                                                       348
          Mechanism of Action                                                                                       348
          R&D Progress                                                                                              348
     Peptide Vaccine + Estramustine - Drug Profile                                                                  350
          Product Description                                                                                       350
          Mechanism of Action                                                                                       350
          R&D Progress                                                                                              350




Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(14)
Prostate Cancer – Pipeline Review, H2 2011


     PROSTVAC + GM-CSF - Drug Profile                                                                                                      351
          Product Description                                                                                                              351
          Mechanism of Action                                                                                                              351
          R&D Progress                                                                                                                     351
     Lupron 6-Month Depot - Drug Profile                                                                                                   353
          Product Description                                                                                                              353
          Mechanism of Action                                                                                                              353
          R&D Progress                                                                                                                     353
     Docetaxel + Estramustine - Drug Profile                                                                                               354
          Product Description                                                                                                              354
          Mechanism of Action                                                                                                              354
          R&D Progress                                                                                                                     354
Prostate Cancer Therapeutics – Drug Profile Updates                                                                                        355
Prostate Cancer Therapeutics - Discontinued Products                                                                                       364
     Prostate Cancer - Featured News                                                                                                       366
          Sep 13, 2011: Bayer To Present New Data On Alpharadin's Pivotal Phase III Study At 2011 ECCO-ESMO Congress                       366
          Sep 12, 2011: Oncothyreon Initiates Phase II Trial Of PX-866 In Patients With Prostate Cancer                                    366
          Sep 07, 2011: Janssen-Cilag Announces Approval Of ZYTIGA In EU For Metastatic Castration-Resistant Prostate Cancer               367
          Sep 06, 2011: OncoGenex Announces Publication Of Phase II Clinical Trial Results Of Custirsen                                    368
          Sep 02, 2011: Exelixis To Provide Update On Cabozantinib At Stifel Nicolaus Healthcare Conference                                369
          Aug 30, 2011: Adamis Begins Phase I/IIa Clinical Prostate Study                                                                  369
          Aug 23, 2011: FDA Grants Fast Track Designation To Bayer’s Alpharadin For Castration Resistant Prostate Cancer In Patients With Bone
          Metastases                                                                                                                        370
          Aug 22, 2011: Amgen Announces PDUFA Date For XGEVA Supplemental Biologics License Application                                    370
          Aug 11, 2011: Advaxis Completes Pre-IND Meeting With FDA On Development Plan For ADXS-PSA                                        371
          Jul 28, 2011: Bavarian Nordic Announces Publication Of New Article On PROSTVAC And Other Immunotherapies For Prostate Cancer372
Appendix                                                                                                                                   373
     Methodology                                                                                                                           373
          Coverage                                                                                                                         373
          Secondary Research                                                                                                               373
          Primary Research                                                                                                                 373
          Expert Panel Validation                                                                                                          374
     Contact Us                                                                                                                            374
     Disclaimer                                                                                                                            374




Prostate Cancer – Pipeline Review, H2 2011                                                            GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                   Page(15)
Prostate Cancer – Pipeline Review, H2 2011




Lis t o f Ta b le s
Number of Products Under Development for Prostate Cancer, H2 2011                                                    28

Products under Development for Prostate Cancer – Comparative Analysis, H2 2011                                       29

Number of Products under Development by Companies, H2 2011                                                           31

Number of Products under Development by Companies, H2 2011                                                           32

Number of Products under Development by Companies, H2 2011                                                           33

Number of Products under Development by Companies, H2 2011                                                           34

Number of Products under Development by Companies, H2 2011                                                           35

Number of Products under Development by Companies, H2 2011                                                           36

Number of Products under Development by Companies, H2 2011                                                           37

Number of Products under Development by Companies, H2 2011                                                           38

Number of Products under Development by Companies, H2 2011                                                           39

Number of Products under Investigation by Universities/Institutes, H2 2011                                           41

Number of Products under Investigation by Universities/Institutes, H2 2011                                           42

Number of Products under Investigation by Universities/Institutes, H2 2011                                           43

Number of Products under Investigation by Universities/Institutes, H2 2011                                           44

Number of Products under Investigation by Universities/Institutes, H2 2011                                           45

Number of Products under Investigation by Universities/Institutes, H2 2011                                           46

Number of Products under Investigation by Universities/Institutes, H2 2011                                           47

Number of Products under Investigation by Universities/Institutes, H2 2011                                           48

Number of Products under Investigation by Universities/Institutes, H2 2011                                           49

Number of Products under Investigation by Universities/Institutes, H2 2011                                           50

Number of Products under Investigation by Universities/Institutes, H2 2011                                           51

Number of Products under Investigation by Universities/Institutes, H2 2011                                           52

Comparative Analysis by Late Stage Development, H2 2011                                                              53

Comparative Analysis by Mid Clinical Stage Development, H2 2011                                                      54

Comparative Analysis by Early Clinical Stage Development, H2 2011                                                    55

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011                                        56

Products under Development by Companies, H2 2011                                                                     57

Products under Development by Companies, H2 2011                                                                     58

Products under Development by Companies, H2 2011                                                                     59

Products under Development by Companies, H2 2011                                                                     60

Products under Development by Companies, H2 2011                                                                     61


Prostate Cancer – Pipeline Review, H2 2011                                                GMDHC1304IDB / Pub September 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(16)
Prostate Cancer – Pipeline Review, H2 2011


Products under Development by Companies, H2 2011                                                                     62

Products under Development by Companies, H2 2011                                                                     63

Products under Development by Companies, H2 2011                                                                     64

Products under Development by Companies, H2 2011                                                                     65

Products under Development by Companies, H2 2011                                                                     66

Products under Development by Companies, H2 2011                                                                     67

Products under Development by Companies, H2 2011                                                                     68

Products under Development by Companies, H2 2011                                                                     69

Products under Development by Companies, H2 2011                                                                     70

Products under Development by Companies, H2 2011                                                                     71

Products under Development by Companies, H2 2011                                                                     72

Products under Development by Companies, H2 2011                                                                     73

Products under Development by Companies, H2 2011                                                                     74

Products under Development by Companies, H2 2011                                                                     75

Products under Development by Companies, H2 2011                                                                     76

Products under Development by Companies, H2 2011                                                                     77

Products under Development by Companies, H2 2011                                                                     78

Products under Development by Companies, H2 2011                                                                     79

Products under Investigation by Universities/Institutes, H2 2011                                                     80

Products under Investigation by Universities/Institutes, H2 2011                                                     81

Products under Investigation by Universities/Institutes, H2 2011 
				
DOCUMENT INFO
Description: Prostate Cancer - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Prostate Cancer - Pipeline Review, H2 2011', provides an overview of the Prostate Cancer therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. 'Prostate Cancer - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Prostate Cancer. - A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Prostate Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries